National Bank of Canada
MRVI icon

National Bank of Canada’s Maravai LifeSciences MRVI Stock Holding History

National Bank of Canada’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-101
Closed -$328 – 3118
2025
Q4 		$328 Sell
101
-35
-26% -$118 ﹤0.01% 2718
2025
Q3 		$390 Buy
136
+35
+35% +$89 ﹤0.01% 2709
2025
Q2 		$241 Hold
101
– – ﹤0.01% 2811
2025
Q1 		$220 Buy
+101
New +$399 ﹤0.01% 2686
2024
Q3 		– Sell
-70
Closed -$485 – 2943
2024
Q2 		$485 Sell
70
-178,000
-100% -$1.54M ﹤0.01% 2569
2024
Q1 		$1.86M Sell
178,070
-25,955
-13% -$176K ﹤0.01% 1021
2023
Q4 		$1.38M Buy
204,025
+203,985
+509,963% +$1.32M ﹤0.01% 1070
2023
Q3 		$385 Hold
40
– – ﹤0.01% 2665
2023
Q2 		$497 Sell
40
-486,293
-100% -$6.56M ﹤0.01% 2615
2023
Q1 		$6.81M Buy
486,333
+354,300
+268% +$5.09M 0.02% 517
2022
Q4 		$1.89M Buy
132,033
+132,008
+528,032% +$2.08M ﹤0.01% 898
2022
Q3 		$1K Hold
25
– – ﹤0.01% 2608
2022
Q2 		$1K Hold
25
– – ﹤0.01% 2701
2022
Q1 		$1K Hold
25
– – ﹤0.01% 2789
2021
Q4 		$1K Buy
+25
New +$1.01K ﹤0.01% 2754

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada's MRVI Position: Q1 2026 in Review

National Bank of Canada sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 101 shares — an estimated $328 sold.

National Bank of Canada first reported a position in MRVI in Q4 2021 and held it in 15 quarters. The position peaked at $6.81M in Q1 2023. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • National Bank of Canada reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
  • National Bank of Canada sold 101 Maravai LifeSciences shares in Q1 2026, an estimated $328.
  • National Bank of Canada first reported a position in Maravai LifeSciences in Q4 2021 and held it in 15 quarters.
  • National Bank of Canada's Maravai LifeSciences position peaked at $6.81M in Q1 2023.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.